Skip to Main

Dhruv Jayanth joined Boston Consulting Group in London in 2016. He is a core member of BCG’s Health Care practice focused on the intersection of science and technology. Dhruv specializes in the biopharma industry, specifically on driving productivity improvements, primarily in R&D, through advanced analytics and refreshing portfolio strategy, as well as through broader cost optimization.

Dhruv has particular expertise in AI and GenAI, from both strategic and technical perspectives, with hands-on experience in a number of different life sciences contexts in R&D and beyond.

Outside of biopharma, Dhruv also has significant experience in other health care divisions, including payer-provider health care and global health, in addition to other cross-functional areas such as business model innovation, M&A, and post-merger integration.

AREAS OF EXPERTISE

EDUCATION

  • Masters in Molecular and Cellular Biochemistry, University of Oxford
  • Undergraduate degree in Molecular and Cellular Biochemistry, University of Oxford

Publications and Videos

Data science in pharmaceutical R&D: the DISRUPT-DS industry roundtable |Hero

Data Science in Pharmaceutical R&D: The DISRUPT-DS Industry Roundtable

Pharmaceutical R&D is transforming with new biology, AI, and data science to improve efficiency and innovation. The DISRUPT-DS roundtable aims to foster industry collaboration.
NEW | BCG Publication Placeholder 4

How Successful Are AI-Discovered Drugs in Clinical Trials? A First Analysis and Emerging Lessons

A growing number of drugs and vaccines have been discovered using AI. However, questions remain about the success of these molecules in clinical trials. The authors conducted a first analysis of the clinical pipelines of AI-native biotech companies.
" "

Biopharma’s Path to Value with Generative AI

Implementing GenAI is not easy in an industry with a complex value chain and intensive regulatory oversight. Companies will wrestle with both choice and complexity.